J. Sagert

发表

PKCα Attenuates Jagged-1–Mediated Notch Signaling in ErbB-2–Positive Breast Cancer to Reverse Trastuzumab Resistance

I. Ellis, K. Albain, A. Filipović, 2015, Clinical Cancer Research.

Title: PKCα Attenuates Jagged-1-mediated Notch Signaling in ErbB-2 positive Breast Cancer to Reverse Trastuzumab Resistance Authors/Affiliations:

I. Ellis, K. Albain, A. Filipović, 2015 .

Giant bent-core mesogens in the thread forming process of marine mussels.

P. Hansma, J. Waite, T. Gutsmann, 2004, Biomacromolecules.

Hyperunstable matrix proteins in the byssus of Mytilus galloprovincialis

J. Waite, J. Sagert, 2009, Journal of Experimental Biology.

Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index

Paul H. Bessette, A. Yang, O. Vasiljeva, 2013, Science Translational Medicine.

Glycosylated Hydroxytryptophan in a Mussel Adhesive Protein from Perna viridis*

J. Waite, D. Hwang, J. Sagert, 2009, The Journal of Biological Chemistry.

Antimicrobial resistance and co-selection phenomenon in Listeria spp. recovered from food and food production environments.

M. Gilmour, A. Woźniak, K. Allen, 2013, Food microbiology.

Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate

O. Vasiljeva, M. Belvin, W. Kavanaugh, 2022, Molecular cancer therapeutics.

Chemical Subtleties of Mussel and Polychaete Holdfasts

J. Waite, Chengjun Sun, J. Sagert, 2006 .

Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents

O. Vasiljeva, M. Belvin, W. Kavanaugh, 2021, Cancer Immunology Research.

A leucine-rich repeat region is conserved in pollen extensin-like (Pex) proteins in monocots and dicots

S. McCormick, S. Stratford, A. Showalter, 2001, Plant Molecular Biology.

CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

Matthew J. Frigault, W. Curry, H. Darr, 2019, Journal of Immunotherapy for Cancer.

Abstract 2664: An anti-Jagged-1/-2 Probody demonstrates inhibition of Jagged-dependent Notch signaling and is activated in multiple types of tumors

O. Vasiljeva, H. Lowman, L. Desnoyers, 2014 .

Abstract 2665: Transforming Notch ligands into tumor-antigen targets: A Probody-Drug Conjugate (PDC) targeting Jagged 1 and Jagged 2

O. Vasiljeva, H. Lowman, L. Desnoyers, 2014 .

Abstract 4570: Development of a proteolytically activatable EGFR Probody for cancer therapy.

A. Yang, O. Vasiljeva, D. Hostetter, 2013 .

Targeting Drug Conjugates to the Tumor Microenvironment: Probody Drug Conjugates

J. Sagert, Jacki Lin, 2018 .

Quantitative Systems Pharmacology Model of a Masked, Tumor‐Activated Antibody

J. Burke, M. Stroh, J. Sagert, 2019, CPT: pharmacometrics & systems pharmacology.

Preclinical Development of CTX120, an Allogeneic CAR-T Cell Targeting Bcma

D. Kalaitzidis, J. Terrett, D. R. Henderson, 2018, Blood.

Abstract 2975: Development of a probody drug conjugate (PDC) targeting CD71 for the treatment of solid tumors and lymphomas

W. Kavanaugh, J. Terrett, Yuanhui Huang, 2016 .

Signaling Node at TSC2 S1365 Potently Regulates T-Cell Differentiation and Improves Adoptive Cellular Cancer Therapy

D. Kass, J. Powell, Jiayu Wen, 2023, bioRxiv.

Glycosylated Hydroxytryptophan in a Mussel Adhesive Protein from Perna viridis*

J. Sagert, Hua Zhao, J. Herbert Waite, 2009, The Journal of Biological Chemistry.